Adverse Drug Reactions
Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
Published in Cancer Weekly, April 1st, 2008
Cardiome Pharma Corp. (NASDAQ:CRME/TSX:)(NASDAQ:COM) announced positive interim clinical results from its 90-day Phase 2b study of vernakalant (oral). The interim analysis demonstrated statistically significant efficacy for the patient group receiving 500mg b.i.d. of vernakalant (oral) as compared to placebo. The safety data from the interim analysis also suggests that vernakalant (oral) was well-tolerated in the atrial fibrillation population studied during the dosing period under analysis.
A Kaplan-Meier analysis of the 446 patients included in the interim dataset demonstrated a significant efficacy benefit for the 500mg dosing group as compared to placebo (two-sided,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-04-01)
More Articles from Cancer Weekly
- Breast Cancer
Make Your Mammogram a Positive Experience: Author Offers Guidelines and Tips to Change Women's Negative Attitudes Toward Mammograms - Breast Cancer
Review of Data from Eight U.S. Cancer Institutions Supports Use of Hyperthermia with Radiation for Treating Recurrent Breast Cancer - Cancer
'A Journal for Karen': Author Shares Gift of Love for Sister with Readers Everywhere Touched by Cancer - Cancer
Enzon's PEG-SN38 Featured in Clinical Cancer Research - Cancer Gene Therapy
Investigators at Lanzhou University target cancer gene therapy - Cancer Gene Therapy
Research from M. Lakatosovaandelova and colleagues provide new insights into cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
